We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

IDL BIOTECH AB

IDL Biotech AB is a diagnostic company that develops, produces and markets IVD tests worldwide for the healthcare sec... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Nomograms Including Rapid Antigen Test Detects Primary Bladder Cancer

By LabMedica International staff writers
Posted on 04 Jan 2022
Print article
Image: The UBC Rapid is a qualitative test to detect cytokeratin fragments 8 and 18 in urine for bladder cancer detection (Photo courtesy of IDL Biotech)
Image: The UBC Rapid is a qualitative test to detect cytokeratin fragments 8 and 18 in urine for bladder cancer detection (Photo courtesy of IDL Biotech)
Urinary bladder cancer (BC) is the tenth most prevalent cancer affecting mainly the elderly and men. The suspicion of BC often arises after the detection of microscopic or macroscopic (gross) hematuria during a patient’s examination.

An accurate urinary marker for BC could be valuable in identifying high-risk patients and reducing the number of control cystoscopies. The broad spectrum of point-of-care (POC) urinary analysis tests currently available facilitates the rapid, non-invasive, and cost-efficient determination of urinary markers, but have a high rate of false positives.

A large international team of Urologists and their colleagues led by those at the Charité - Universitätsmedizin Berlin (Berlin, Germany) analyzed data from 1,787 patients from 13 participating centers tested between 2012 and 2020, including 763 patients with BC. Urine samples were analyzed with the UBC Rapid Test ((IDL Biotech, Bromma, Sweden). The results were quantified by the Concile Ω 100 POC reader (Concile, Freiburg, Germany).

The nomograms were developed using data from 320 patients and externally validated using data from 274 patients. The diagnostic accuracy of the UBC Rapid Test was evaluated using receiver operating characteristics analysis. Brier scores and calibration curves were chosen for validation. Biopsy-proven BC was predicted using multivariate logistic regression.

The investigators reported that the sensitivity, specificity, and area under the curve for the UBC Rapid Test were 46.4%, 75.5%, and 0.61 for low-grade (LG-) BC, and 70.5%, 75.5%, and 0.73 for high-grade (HG-) BC, respectively. Age, UBC Rapid Test results, smoking status, and hematuria were identified as independent predictors of primary BC. After external validation, nomograms based on these predictors resulted in an area under the curve of 0.79 and 0.95 in predicting LG-BC and HG-BC, respectively, showing excellent calibration associated with a higher net benefit than the UBC Rapid Test alone for low and medium risk levels in decision curve analysis.

The authors concluded that the UBC Rapid Test alone has limited clinical utility for predicting the presence of BC. However, its combined use with BC risk factors including age, smoking status, and hematuria provides a fast, highly accurate, and non-invasive tool for screening patients for primary LG-BC and especially primary HG-BC. The study was published on December 20, 2021 in the British Journal of Urology.

Related Links:
Charité - Universitätsmedizin Berlin
IDL Biotech
Concile


New
Gold Supplier
Quantitative Immunoassay Analyzer
FIA8000
New
Infliximab Rapid Test
Quantum Blue Infliximab
New
POC BNP Fluorescence Immunoassay
Quidel Triage BNP Test
New
Silver Supplier
Hemoglobin Testing System
VARIANT II TURBO

Print article

Channels

Molecular Diagnostics

view channel
Image: The new multiplex QIAstat-Dx Viral Vesicular Panel is designed to support research and surveillance efforts (Photo courtesy of QIAGEN)

First Syndromic Test Differentiates Between Monkeypox and Five Pathogens with Similar Symptoms

A new syndromic test differentiates between monkeypox and five other pathogens which cause similar symptoms. This first-ever test detects the two known forms of monkeypox virus (the so-called West African... Read more

Industry

view channel
Image: The Accelerate Arc Module & BC kit is registered as an IVD (Photo courtesy of Accelerate Diagnostics)

BD and Accelerate Diagnostics Collaborate to Offer Rapid Antimicrobial Identification and Susceptibility Diagnostics

Becton, Dickinson and Company (BD, Franklin Lakes, NJ, USA) and Accelerate Diagnostics, Inc. (Tucson, AZ, USA) have entered into a worldwide commercial collaboration agreement where BD will offer Accelerate's... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.